First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

Davis, EJ; Martin-Liberal, J; Kristeleit, R; Cho, DC; Blagden, SP; Berthold, D; Cardin, DB; Vieito, M; Miller, RE; Dass, PH; Orcurto, A; Spencer, K; Janik, JE; Clark, J; Condamine, T; Pulini, J; Chen, XJ; Mehnert, JM

Mehnert, JM (通讯作者)，Rutgers State Univ, New Brunswick, NJ 08901 USA.

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022; 10 (10):

Abstract

Background OX40 is a costimulatory receptor upregulated on antigen-activated T cells and constitutively expressed on regulatory T cells (Tregs). INCAG......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索